Vasella Knocks AstraZeneca Acquisition Rumor
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis CEO Daniel Vasella dismissed rumors that the firm is considering acquisition of rival drug maker AstraZeneca July 17
You may also be interested in...
Novartis Eyes Q3 NeuTec Acquisition Closing
The Swiss drug maker says it has acquired just over 75% of NeuTec shares.
Novartis/Chiron Deal To Close April 20
Novartis' acquisition of Chiron is set to close on April 20, the firms said April 19
Novartis Boosts Sandoz Generic Business With Acquisition Of Eon, Hexal
Addition of U.S., German companies will make Sandoz the global leader in generic sales, with combined 2004 pro forma revenues of $5.1 bil., Novartis says. Acquisition will enable Sandoz to become the "preferred partner" for "authorized" generic deals and to play a leading role in development of follow-on biologics.